Submitted Successfully!
To reward your contribution, here is a gift for you: A free trial for our video production service.
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Version Summary Created by Modification Content Size Created at Operation
1
Decio Armanini
 -- 1314 2022-04-22 18:22:04 |
2 format change
Peter Tang
Meta information modification 1314 2022-04-24 03:56:01 |

Video Upload Options

Do you have a full video?
Send video materials Upload full video

Confirm

Are you sure to Delete?
Yes No
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
Armanini, D.; , .; Bordin, L.; Sabbadin, C. Controversies in Pathogenesis of Polycystic Ovary Syndrome. Encyclopedia. Available online: https://encyclopedia.pub/entry/22183 (accessed on 30 June 2024).
Armanini D,  , Bordin L, Sabbadin C. Controversies in Pathogenesis of Polycystic Ovary Syndrome. Encyclopedia. Available at: https://encyclopedia.pub/entry/22183. Accessed June 30, 2024.
Armanini, Decio, , Luciana Bordin, Chiara Sabbadin. "Controversies in Pathogenesis of Polycystic Ovary Syndrome" Encyclopedia, https://encyclopedia.pub/entry/22183 (accessed June 30, 2024).
Armanini, D., , ., Bordin, L., & Sabbadin, C. (2022, April 22). Controversies in Pathogenesis of Polycystic Ovary Syndrome. In Encyclopedia. https://encyclopedia.pub/entry/22183
Armanini, Decio, et al. "Controversies in Pathogenesis of Polycystic Ovary Syndrome." Encyclopedia. Web. 22 April, 2022.
Controversies in Pathogenesis of Polycystic Ovary Syndrome
Edit
This entry is adapted from the peer-reviewed paper 10.3390/ijms23084110

Polycystic ovary syndrome (PCOS) is a heterogeneous and extremely common disease with symptoms that vary with the age of the patient, typically characterized by hyperandrogenism, chronic oligo-anovulation, and/or several metabolic disorders. The syndrome includes various phenotypes, and the pathogenesis is multifactorial, often involving insulin resistance. This feature is closely related to ovarian dysfunction, inflammation, hyperandrogenism, and metabolic disorders, which characterize and complicate the syndrome. Therapy currently considers both lifestyle improvements and medications, and must be tailored on a case-by-case basis. To date, the published studies have not arrived at a definition of the most suitable therapy for each individual case and many of the drugs used are still off-label.

polycystic ovary syndrome insulin resistance aldosterone hyperandrogenism metformin inositol insulin sensitizers spironolactone

1. Introduction

Polycystic ovary syndrome (PCOS) is the most common endocrine disease in women of reproductive age. Its prevalence varies greatly depending on the diagnostic criteria used, from 4–8% according to NIH/NICHD criteria, to approximately 18% according to the Rotterdam criteria [1]. An international evidence-based guideline for the evaluation and management of PCOS more recently endorses and suggests the use of the Rotterdam diagnostic criteria [2]. PCOS is a heterogeneous and extremely common disease, with symptoms that vary with the age of the patient and with therapies that must be tailored on a case-by-case basis. Its typical expression is represented by hyperandrogenism with ovarian dysfunction, chronic oligo-anovulation, and/or micropolycystic morphology of the ovary. Guidelines generally focus on the symptoms of PCOS, but remain more elusive regarding the mechanisms leading to the disease, such as insulin resistance, a very common condition in PCOS, which is worsened by hyperandrogenism-related adipose tissue accumulation [3] and is involved in both the pathogenesis and the progression of the disease [4]. Furthermore, apart from the use of estrogen–progestin, no drug has been approved specifically to counteract metabolic abnormalities and hyperandrogenism, so most drugs are administered off-label.

2. The Pathogenetic Role of Insulin Resistance in PCOS

Insulin acts as a regulator of glucose homeostasis by stimulating glucose uptake by insulin-sensitive tissues, such as adipose tissue, skeletal muscle, liver, and heart, but also by suppressing hepatic glucose production. Insulin is also able to suppress lipolysis, leading to a decrease in free fatty acid levels, which may mediate insulin’s action on hepatic glucose production. Insulin resistance is defined as a decreased ability of insulin to carry out these metabolic actions inherent in glucose uptake and production and lipolysis, thus leading to compensatory high insulin levels, both at baseline and after glucose loading, if pancreatic function is normal. There is still no consensus on the exact mechanism that leads to insulin resistance in PCOS, regardless of body mass index (BMI). An old study argued that in PCOS, the mechanism underlying insulin resistance decreased autophosphorylation of the insulin receptor following insulin binding [5].
The mechanisms by which insulin resistance exerts its effects have only recently been well described [6]. At a liver and skeletal muscle level, insulin resistance increases lipolysis with the accumulation of non-esterified fatty acids. The accumulation of intrahepatic lipids activates the diacylglycerol/protein kinase C axis and inhibits the insulin receptor, also affecting insulin signaling and subsequent gluconeogenesis. In skeletal muscle, the inhibition of phosphoinositide-3 kinase and phosphorylation of insulin receptor substrate 1 leads to impaired insulin signaling by altering the GLUT-4 expression and glucose uptake [6][7]. The consequence of hyperinsulinemia compensatory to insulin resistance is an overstimulation of non-insulin-sensitive tissues, such as the ovaries. In particular, insulin and LH act synergistically on the theca cells, stimulating ovarian androgen production [4]. In addition, insulin acts both directly as a co-gonadotropin, enhancing LH activity by stimulating the expression of receptors for LH, insulin, and IGF on granulosa cells, and indirectly by impairing the regulation of the hypothalamic–pituitary–ovarian axis. Hyperinsulinemia increases the adrenal steroid response to ACTH stimuli and decreases the synthesis of sex hormone binding globulin (SHBG) in the liver, with a consequent increase of both total and free androgen levels (Figure 1).
Figure 1. Pathophysiology and potential therapeutic targets of PCOS.
Recent studies have hypothesized the role of the gut microbiome as a cause or effect of BMI, insulin resistance, and inflammation in PCOS. Gut dysbiosis due to poor-quality diet could cause the passage of lipopolysaccharides produced by Gram negative micro-organisms into the circulation. The consequence could be the activation of the immune system, insulin resistance, and hyperandrogenism [8]. A recent revision of 31 studies published in the last 10 years reported reduced alpha diversity and dysbiosis in women with PCOS [9]. Treatment of PCOS with prebiotics, probiotics, and synbiotics could have some beneficial effects on metabolic and biochemical profiles. Further studies should investigate the role of the microbiome in the pathogenesis and management of PCOS.

3. The Pathogenetic Role of Inflammation in PCOS

PCOS has also been associated with chronic low-grade inflammation, characterized by increased white blood cell count, high levels of C-reactive protein (CRP), interleukin 6 (IL-6), interleukin 18 (IL-18), monocyte chemoattractant protein-1, and macrophage inflammatory protein-1. Insulin resistance is related to inflammation. For example, an exaggerated production of tumor necrosis factor (TNF-α) produced by monocytes as a response to hyperglycemia could exacerbate the metabolic and hormonal abnormalities of PCOS [10]. Recently, advanced glycosylation end products (AGEs) and their receptors implicated in the inflammation and oxidative stress cascades have also been found to be overexpressed in PCOS women [11]. The release of inflammatory markers is associated with long-term metabolic complications and high cardiovascular risk [12].
An underestimated factor in the diagnosis and treatment of PCOS is aldosterone [13]. It has been shown that aldosterone and, in particular, the aldosterone/renin ratio are often increased in PCOS, and this accentuates the underlying inflammatory state and might be involved in the development of some metabolic and cardiovascular disorders [14]. The researchers characterized aldosterone receptors in human mononuclear leukocytes [15], and subsequent studies confirmed that the incubation of lymphocytes with excess aldosterone increased the protein expression of PAI 1 and p22phox, two markers of inflammation [16]. Many studies have reported the role of mineralocorticoid receptor blockers, such as spironolactone, not only in the treatment of hyperaldosteronism and resistant hypertension, but also in the prevention of metabolic and cardiovascular complications and cerebrovascular accidents in patients with normal values of aldosterone [17].
Another important pro-inflammatory agent involved in the pathogenesis of PCOS is adipose tissue [18]. It is known that adipose tissue-resident macrophages release TNF-α and IL-6, which are implicated in the induction of insulin resistance [19]. Hyperandrogenism leads to aberrant adipose tissue functions in PCOS [20]. Insulin resistance, hyperandrogenism, chronic low-grade inflammation, and adipose tissue hypertrophy and dysfunction may act together in a vicious cycle in the pathophysiology of PCOS. These observations need confirmation in larger studies directly assessing the presence of inflammation in the fat tissues of PCOS women [21].

4. The Pathogenetic Role of Hyperandrogenism in PCOS

Hyperandrogenism in PCOS could be caused by defective intrinsic steroidogenesis in ovarian theca cells [11] or by elevated LH levels due to altered regulation of the hypothalamic–pituitary axis, also influenced by insulin. Alterations in adrenal steroidogenesis due to CYP17α1 hyperactivation [22] could also contribute to the hyperandrogenism of PCOS [23]. Increased peripheral cortisol metabolism has also been proposed as a contributor to adrenal hyperandrogenism. Reduced cortisol levels cause inadequate negative feedback on the hypothalamic–pituitary–adrenal axis with increased pituitary ACTH synthesis and stimulation of adrenal steroidogenesis [24]. If insulin resistance leads to hyperandrogenism and anovulation, hyperandrogenism is also recognized as one of the possible causes of insulin resistance in PCOS (Figure 1). Androgen excess during intrauterine life or in the immediate post-natal period has been shown to accentuate visceral adiposity and insulin resistance. Hyperandrogenic PCOS phenotypes show an increased level of insulin resistance and metabolic complications [25]. The administration of drugs with anti-androgenic activity improves insulin resistance [26]. At the level of adipose tissue, testosterone acts by decreasing protein kinase C (PKC) phosphorylation [27], whereas on skeletal muscle, it acts by increasing the phosphorylation of the mammalian target of rapamycin (mTOR) and ribosomal kinase S6 (S6K), leading to increased serine phosphorylation of IRS-1 [28]. These two androgen-mediated mechanisms exacerbate insulin resistance in adipose tissue and skeletal muscle, respectively.

References

  1. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 Consensus on Diagnostic Criteria and Long-Term Health Risks Related to Polycystic Ovary Syndrome (PCOS). Hum. Reprod. 2004, 19, 41–47.
  2. Teede, H.J.; Misso, M.L.; Costello, M.F.; Dokras, A.; Laven, J.; Moran, L.; Piltonen, T.; Norman, R.J.; International PCOS Network. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Clin. Endocrinol. 2018, 89, 251–268.
  3. Dumesic, D.A.; Abbott, D.H.; Sanchita, S.; Chazenbalk, G.D. Endocrine-metabolic dysfunction in polycystic ovary syndrome: An evolutionary perspective. Curr. Opin. Endocr. Metab. Res. 2020, 12, 41–48.
  4. Diamanti-Kandarakis, E.; Dunaif, A. Insulin resistance and the polycystic ovary syndrome revisited: An update on mechanisms and implications. Endocr. Rev. 2012, 33, 981–1030.
  5. Dunaif, A.; Segal, K.R.; Shelley, D.R.; Green, G.; Dobrjansky, A.; Licholai, T. Evidence for distinctive and intrinsic defects in insulin action in polycystic ovary syndrome. Diabetes 1992, 41, 1257–1266.
  6. Petersen, M.C.; Shulman, G.I. Mechanisms of insulin action and insulin resistance. Physiol. Rev. 2018, 98, 2133–2223.
  7. Diamanti-Kandarakis, E.; Papavassiliou, A.G. Molecular mechanisms of insulin resistance in polycystic ovary syndrome. Trends Mol. Med. 2006, 12, 324–332.
  8. Tremellen, K.; Pearce, K. Dysbiosis of Gut Microbiota (DOGMA)—A novel theory for the development of Polycystic Ovarian Syndrome. Med. Hypotheses 2012, 79, 104–112.
  9. Parker, J.; O’Brien, C.; Hawrelak, J. A narrative review of the role of gastrointestinal dysbiosis in the pathogenesis of polycystic ovary syndrome. Obstet. Gynecol. Sci. 2022, 65, 14–28.
  10. Yildiz, B.O.; Knochenhauer, E.S.; Azziz, R. Impact of obesity on the risk for polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 2008, 93, 162–168.
  11. Diamanti-Kandarakis, E. Polycystic ovarian syndrome: Pathophysiology, molecular aspects and clinical implications. Expert Rev. Mol. Med. 2008, 10, e3.
  12. Rudnicka, E.; Suchta, K.; Grymowicz, M.; Calik-Ksepka, A.; Smolarczyk, K.; Duszewska, A.M.; Smolarczyk, R.; Meczekalski, B. Chronic low grade inflammation in pathogenesis of PCOS. Int. J. Mol. Sci. 2021, 22, 3789.
  13. Sabbadin, C.; Andrisani, A.; Ambrosini, G.; Bordin, L.; Donà, G.; Manso, J.; Ceccato, F.; Scaroni, C.; Armanini, D. Aldosterone in gynecology and its involvement on the risk of hypertension in pregnancy. Front. Endocrinol. 2019, 10, 575.
  14. Armanini, D.; Bordin, L.; Donà, G.; Sabbadin, C.; Bakdounes, L.; Ragazzi, E.; Giorgino, F.L.; Fiore, C. Polycystic ovary syndrome: Implications of measurement of plasma aldosterone, renin activity and progesterone. Steroids 2012, 77, 655–658.
  15. Armanini, D.; Strasser, T.; Weber, P.C. Binding of agonists and antagonists to mineralocorticoid receptors in human peripheral mononuclear leucocytes. J. Hypertens. Suppl. 1985, 3, S157–S159.
  16. Calò, L.A.; Zaghetto, F.; Pagnin, E.; Davis, P.A.; De Mozzi, P.; Sartorato, P.; Martire, G.; Fiore, C.; Armanini, D. Effect of aldosterone and glycyrrhetinic acid on the protein expression of PAI-1 and p22(phox) in human mononuclear leukocytes. J. Clin. Endocrinol. Metab. 2004, 89, 1973–1976.
  17. Pitt, B.; Zannad, F.; Remme, W.J.; Cody, R.; Castaigne, A.; Perez, A.; Palensky, J.; Wittes, J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone evaluation study investigators. N. Engl. J. Med. 1999, 341, 709–717.
  18. Makki, K.; Froguel, P.; Wolowczuk, I. Adipose tissue in obesity-related inflammation and insulin resistance: Cells, cytokines, and chemokines. ISRN Inflamm. 2013, 2013, 139239.
  19. Tilg, H.; Moschen, A.R. Inflammatory mechanisms in the regulation of insulin resistance. Mol. Med. 2008, 14, 222–231.
  20. Shorakae, S.; Ranasinha, S.; Abell, S.; Lambert, G.; Lambert, E.; de Courten, B.; Teede, H. Inter-related effects of insulin resistance, hyperandrogenism, sympathetic dysfunction and chronic inflammation in PCOS. Clin. Endocrinol. 2018, 89, 628–633.
  21. Aboeldalyl, S.; James, C.; Seyam, E.; Ibrahim, E.M.; Shawki, H.E.; Amer, S. The role of chronic inflammation in polycystic ovarian syndrome-A systematic review and meta-analysis. Int. J. Mol. Sci. 2021, 22, 2734.
  22. Yildiz, B.O.; Woods, K.S.; Stanczyk, F.; Bartolucci, A.; Azziz, R. Stability of adrenocortical steroidogenesis over time in healthy women and women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 2004, 89, 5558–5562.
  23. Rosenfield, R.L. Ovarian and adrenal function in polycystic ovary syndrome. Endocrinol. Metab. Clin. N. Am. 1999, 28, 265–293.
  24. Tsilchorozidou, T.; Honour, J.W.; Conway, G.S. Altered cortisol metabolism in polycystic ovary syndrome: Insulin enhances 5alpha-reduction but not the elevated adrenal steroid production rates. J. Clin. Endocrinol. Metab. 2003, 88, 5907–5913.
  25. Moghetti, P.; Tosi, F.; Bonin, C.; Di Sarra, D.; Fiers, T.; Kaufman, J.M.; Giagulli, V.A.; Signori, C.; Zambotti, F.; Dall’Alda, M.; et al. Divergences in insulin resistance between the different phenotypes of the polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 2013, 98, E628–E637.
  26. Armanini, D.; Andrisani, A.; Bordin, L.; Sabbadin, C. Spironolactone in the treatment of polycystic ovary syndrome. Expert Opin. Pharmacother. 2016, 17, 1713–1715.
  27. Corbould, A. Chronic testosterone treatment induces selective insulin resistance in subcutaneous adipocytes of women. J. Endocrinol. 2007, 192, 585–594.
  28. Allemand, M.C.; Irving, B.A.; Asmann, Y.W.; Klaus, K.A.; Tatpati, L.; Coddington, C.C.; Nair, K.S. Effect of testosterone on insulin stimulated IRS1 Ser phosphorylation in primary rat myotubes—A potential model for PCOS-related insulin resistance. PLoS ONE 2009, 4, e4274.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
Upload a video for this entry
Information
Subjects: Medicine, General & Internal
Contributors MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :
Decio Armanini
,
,
Luciana Bordin
,
Chiara Sabbadin
View Times: 395
Revisions: 2 times (View History)
Update Date: 24 Apr 2022
Table of Contents
    1000/1000
    Hot Most Recent
    Video Production Service
    Feedback